Key result
AAV-mediated Bcl-xL gene transfer significantly reduced TUNEL-positive cells and maintained cell density after glutamate exposure in motor neuron models.
Population
In vitro models of motor neuron disease using SH-SY5Y cells and embryonic day 15 (E15) motor neurons
Design
Preclinical
Follow-up
48 hours
Authors
Loading...
Hypothesis-generating for ALS gene therapy; leaves open translation from motor neuron models to clinical use.
AAV-mediated overexpression of the antiapoptotic Bcl-xL gene protects motor neurons from glutamate excitotoxicity, suggesting a potential gene therapy approach for ALS.
Garrity‐Moses et al. (2005) studied Amyotrophic lateral sclerosis (ALS). AAV-mediated Bcl-xL gene transfer was evaluated on TUNEL-positive cells and cell density after glutamate exposure. AAV-mediated Bcl-xL gene transfer significantly reduced TUNEL-positive cells and maintained cell density after glutamate exposure in motor neuron models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: